(Aug. 21, 2020) – The Kansas Hospital Association continues to monitor the situation with the 340B Prescription Drug Program and requests from pharmaceutical manufacturers for data related to this program. The Health Resources and Services Administration has made public comments that they believe they do not have the authority to intercede regarding the actions of the drug manufacturers. This is unfortunate, as the threats of these companies appear to threaten the purpose of the program.
KHA encourages members to speak with their legal counsel and their 340B administrator to determine the best course of action. In the meantime, KHA has written a letter of concern to our congressional delegation to make them aware of this issue.